Multi-modality therapy for cancer of the esophagus and GE junction (Q38010632)

26 August 2017

title

Multi-modality therapy for cancer of the esophagus and GE junction (English)

1 reference

26 August 2017

Mohamedtaki A Tejani

1 reference

26 August 2017

Barbara A Burtness

series ordinal

1 reference

26 August 2017

publication date

1 September 2012

1 reference

Current Treatment Options in Oncology

26 August 2017

published in

1 reference

26 August 2017

1 reference

26 August 2017

1 reference

26 August 2017

page(s)

390-402

1 reference

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

The number of lymph node metastases influences survival and International Union Against Cancer tumor-node-metastasis classification for esophageal squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Evidence-based guideline recommendations on the use of positron emission tomography imaging in oesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Impact of 18-fluorodeoxyglucose positron emission tomography on computed tomography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability: PET/CT improves es

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Vascular endothelial growth factor in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

(18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Plasma DNA as a molecular marker for completeness of resection and recurrent disease in patients with esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

A Prospective Study of Tobacco, Alcohol, and the Risk of Esophageal and Gastric Cancer Subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Histologic Tumor Type Is an Independent Prognostic Parameter in Esophageal Cancer: Lessons From More Than 1,000 Consecutive Resections at a Single Center in the Western World

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0193-5

Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer

21 January 2018

1 reference

12 December 2020

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma

1 reference

12 December 2020

Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification

1 reference

12 December 2020

Induction chemoradiotherapy increases pleural and pericardial complications after esophagectomy for cancer

1 reference

12 December 2020

Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus

1 reference

12 December 2020

Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy

1 reference

12 December 2020

The Impact of Time Elapsed Between Endoscopic Ultrasound and Esophagectomy on Concordance of Ultrasonographic and Pathologic Staging of Esophageal Malignancy

1 reference

12 December 2020

Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery

1 reference

12 December 2020

Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus

1 reference

12 December 2020

Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome

1 reference

12 December 2020

Epidemiology of esophageal cancer

1 reference

12 December 2020

Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity

1 reference

12 December 2020

10.1007/S11864-012-0193-5

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1044069828

0 references

1 reference